Natalizumab observational programme: assessment of long-term safety and impact on disease activity and progression of natalizumab in patients with relapsing-remitting multiple sclerosis

被引：0
|
作者：
Wiendl, H.
Butzkueven, H.
Trojano, M.
Goodin, D.
Kappos, L.
Desgrandchamps, D.
机构：
[1] Univ Wurzburg, Wurzburg, Germany
[2] Royal Melbourne Hosp, Melbourne, Vic, Australia
[3] Univ Bari, Bari, Italy
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
[5] Univ Basel Hosp, CH-4031 Basel, Switzerland
[6] Biogen Idec Int GmbH, Zug, Switzerland
来源：
MULTIPLE SCLEROSIS | 2009年 / 15卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S248 / S248
页数：1
相关论文
共 50 条
  • [21] Disease activity and disability progression decrease beyond two years on natalizumab in relapsing multiple sclerosis patients in the TYSABRI® (natalizumab) Observational Programme
    Wiendl, H.
    Butzkueven, H.
    Kappos, L.
    Pellegrini, F.
    Trojano, M.
    Paes, D.
    Zhang, A.
    Belachew, S.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 485 - 485
  • [22] Natalizumab reduces apathy in relapsing-remitting multiple sclerosis patients
    Berkovich, R.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S154 - S155
  • [23] Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis
    Arnal-Garcia, Carmen
    Rosa Garcia-Montero, Ma
    Malaga, Ignacio
    Millan-Pascual, Jorge
    Oliva-Nacarino, Pedro
    Ramio-Torrenta, Lluis
    Oreja-Guevara, Celia
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2013, 17 (01) : 50 - 54
  • [24] Efficacy and safety of natalizumab as escalation therapy in relapsing-remitting multiple sclerosis
    Putzki, Norman
    Kiriaki, Kollia
    Katsarava, Zaza
    Woods, Sophia
    Give, Ezinne
    Diener, H.
    NEUROLOGY, 2008, 70 (11) : A90 - A90
  • [25] Natalizumab Discontinuation: Observational Study of University of Colorado Patients with Relapsing-Remitting Multiple Sclerosis
    Nnunukwe, Ngozi
    Schreiner, Teri
    NEUROLOGY, 2012, 78
  • [26] Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
    Havrdova, Eva
    Galetta, Steven
    Hutchinson, Michael
    Stefoski, Dusan
    Bates, David
    Polman, Chris H.
    O'Connor, Paul W.
    Giovannoni, Gavin
    Phillips, J. Theodore
    Lublin, Fred D.
    Pace, Amy
    Kim, Richard
    Hyde, Robert
    LANCET NEUROLOGY, 2009, 8 (03): : 254 - 260
  • [27] Managing breakthrough disease activity during treatment with natalizumab in relapsing-remitting multiple sclerosis
    Lizak, Nathaniel
    Sharmin, Sifat
    Horakova, Dana
    Havrdova, Eva
    Ayuso, Guillermo Izquierdo
    Madueno, Sara Eichau
    van der Walt, Anneke
    Butzkueven, Helmut
    Lechner-Scott, Jeannette
    Buzzard, Katherine
    Skibina, Olga
    Gerlach, O.
    Prat, Alexandre
    Girard, Marc
    Duquette, Pierre
    Alroughani, Raed
    Patti, Francesco
    Grand'Maison, Francois
    Sa, Maria Jose
    Morales, Eduardo Aguera
    Hodgkinson, Suzanne
    Grammond, Pierre
    Kuhle, Jens
    Yamout, Bassem I.
    Khoury, Samia
    Ozakbas, Serkan
    Slee, Mark
    Csepany, Tunde
    John, Nevin A.
    Laureys, Guy
    Van Hijfte, Liesbeth
    Terzi, Murat
    Amato, Maria Pia
    Boz, Cavit
    Al-Asmi, Abdullah
    Cartechini, Elisabetta
    Gouider, Riadh
    Mrabet, Saloua
    Roos, Izanne
    Kalincik, Tomas
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 370 - 372
  • [28] Associations between baseline factors and on-treatment relapses in natalizumab-treated patients with relapsing-remitting multiple sclerosis in the TYSABRI® (natalizumab) observational programme
    Wiendl, H.
    Butzkueven, H.
    Kappos, L.
    Pellegrini, F.
    Trojano, M.
    Zhang, A.
    Belachew, S.
    JOURNAL OF NEUROLOGY, 2013, 260 : S68 - S68
  • [29] Switching from natalizumab to ocrelizumab in patients with relapsing-remitting multiple sclerosis
    Van Lierop, Z.
    Toorop, A.
    Willemse, E.
    Strijbis, E.
    Kalkers, N.
    Moraal, B.
    Barkhof, F.
    Teunissen, C.
    Killestein, J.
    Van Kempen, Z.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 310 - 311
  • [30] Neurocognitive changes in patients with relapsing-remitting multiple sclerosis treated with natalizumab
    Doehler, N.
    Mueller, S.
    Vehoff, J.
    Galovic, M.
    Tettenborn, B.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 213 - 213
12345